

Alerts Sign In **ASH Home** Blood App My Folders a search Leading the way in experimental and clinical research in hematology Advanced Search About Blood Submit to Blood Classifieds Authors Subscriptions in First Edition Collections All Issues Abstracts Video Library Current Issue Home / December 6, 2014; Blood: 124 (21) 1 No markup for post-processing

## RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT

Frederic Baron, MD PhD<sup>1</sup>, Myriam Labopin, MD\*,<sup>2</sup>,<sup>3</sup>, Andrew Peniket\*,<sup>4</sup>, Pavel Jindra, MD PhD\*,<sup>5</sup>, Boris Afanasyev, MD\*,<sup>6</sup>, Miguel A. Sanz<sup>7</sup>, Eric Deconinck<sup>8</sup>, Arnon Nagler, MD<sup>9</sup>,<sup>3</sup>, and Mohamad Mohty, MD PhD<sup>10</sup>,<sup>11</sup>

PDF

+ Author Affiliations


Info & Metrics

E-Letters

Article

Allesteres	<b>←</b>
Abstract	
•\$	
AN and MM are co-senior authors.	Volur Issue
Background. Fludarabine plus busulfan (FB) and fludarabine plus melphalan	Page: DOI:
(FM) are two widely used reduced-intensity conditioning (RIC) regimens for	DOI.
allogeneic hematopoietic stem cell transplantation (allo-SCT).	≥ E
Patients and Methods. In the current survey, we compared transplantation	<b>P</b> 0
outcomes in a cohort of 394 acute myeloid leukemia (AML) patients given	<b>T</b>
grafts from HLA-identical siblings after FB (n=218; with a total busulfan dose	
ranging between 7.1 and 8.9 mg/kg p.o., or between 6.0 and 6.9 mg/kg i.v.)	<b>②</b> C
or FM (n=176; with a total melphalan dose ranging between 130 and 150	
$$ mg/m $^2$ ). Patients given manipulated grafts and those given T cell depleting	
agents (ATG or alemtuzumab) were not included. At time of transplantation,	Arti
266 patients (68%) were in first complete remission (CR1), 69 (18%) in later	
CR, while 59 patients (15%) had advanced diseases. Three-hundreds and fifty-	Info
two patients (89%) received peripheral blood stem cells while the remaining	E-Le
42 patients received bone marrows as stem cell source.	L-Le
Results. Three FB patients but no FM patients failed to engraft. Median time	
for reaching 500 neutrophils was 17 (1-50) days in FB patients versus 14 (9-	Relat
43) days in FM patients (P<0.001) probably due to the more frequent use of	Kelat
methotrexate in FB patients. Proportion of patients with grade I, II, III and IV	

acute GVHD in FB versus FM patients were 11 versus 14%, 14 versus 16%, 5 versus 7% and 4 versus 3%, respectively (P=0.7). At 2-years, cumulative



incidence of chronic GVHD was 54±4% in FB patients, versus 48±4% in FM patients (P=0.15). After adjusting for variables with different distribution between FB and FM, incidence of chronic GVHD remained similar in FM and in FB patients (HR 0.8, 95% CI 0.6-1.1; P=0.13). Two-year relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS) and overall survival (OS) in FB vs FM patients were 31±3% versus 20±3% (P=0.007), 18±3% versus 20±3% (P=0.4), 51±4% versus 60±4% (P=0.08), and 54±4% versus 62±4% (P=0.2), respectively. Among FB patients given i.v. busulfan (n=81), 2-year RI, NRM, LFS and OS were 26±5%, 25±6%, 49±7% and 54±7%, respectively. Restricting the analyses to patients transplanted in CR1, 2-year RI, NRM, LFS and OS in FB vs FM patients were  $28\pm4\%$  versus  $14\pm3\%$  (P=0.005),  $17\pm3\%$ versus 22±4% (P=0.2), 55±5% versus 64±5% (P=0.2), and 59±4% versus 66±5% (P=0.5), respectively. Among FB patients given i.v. busulfan (n=59), 2-year RI, NRM, LFS and OS were 22±6% (P=0.4 in comparison to FM patients), 23±7% (P=0.5),  $55\pm8\%$  (P=0.2) and  $60\pm7\%$  (P=0.4), respectively. After adjusting for variables with different distribution between FB and FM and associated with p<0.05 in univariate analyses and taking data from all included patients, RI was significantly lower in FM than in FB patients (HR 0.5, 95% CI 0.3-0.8; P=0.01), while there was a suggestion for higher NRM in FM than in FB patients (HR 1.6. 95% CI 0.9-2.7; P=0.1). This translated to similar LFS (HR 0.8, 95% CI 0.6-1.2; P=0.2) and OS (HR 0.9, 95% CI 0.6-1.3; P=0.6) in FM and in FB patients.

Conclusions. These results suggest that although FM provided a better AML control than FB as RIC regimen for allo-SCT, the two regimens provided similar OS. Despite the current survey included a relatively large cohort of patients transplanted only as treatment for AML, multicenter randomized studies are needed to confirm these results.

Disclosures Nagler: Pierre-Fabre Medicament: Honoraria. Mohty: Pierre-Fabre Medicament: Honoraria.


- This icon denotes a clinically relevant abstract

© 2014 by The American Society of Hematology

A Back to top

Articles by Baron, F.
Articles by Mohty, M.

Articles by Baron, F.
Articles by Mohty, M.





How will you treat your patients with the latest available agents?

LEARN FROM THE EXPERTS.





Leading the way in experimental and clinical research in hematology

American Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036 Phone 202-776-0544 | Fax 202-776-0545

Current Issue	Subscriptions	Submit to <i>Blood</i>	Information for:
First Edition	About Blood	Alerts	Authors
Topics	Newsroom	RSS	Subscribers
Collections	Public Access	Blood App	Institutions/Librarians
All Issues	Permissions	Contact Us	Advertisers
Abstracts	Order Reprints	Feedback	ASH Privacy Policy

Blood Journal | RIC Allo-SCT with Flu/Bu in Comparison to Flu/Me... in Similar Overall Survival: A Report from the ALWP of the EBMT

15/11/15 14:21

	ASH Home	Research	Education	Advocacy	Meetings	ASH Store	f	<b>y</b>	in	
--	----------	----------	-----------	----------	----------	-----------	---	----------	----	--

Copyright © 2015 by American Society of Hematology